More good news for those of us working to keep our APOB / LDL-C as low as reasonably possible. Statins, for most people at least, are probably your friend.
People with low levels of low-density lipoprotein cholesterol (LDL-C) in their blood have a lower overall risk of dementia, and a reduced risk of Alzheimer’s disease specifically, according to research published in the Journal of Neurology Neurosurgery & Psychiatry.
Taking statins also provided an “additional protective effect” against the condition for those people with low levels of bad cholesterol, researchers found.
The Paper: (Open access)
Low-density lipoprotein cholesterol levels and risk of incident dementia: a distributed network analysis using common data models
Results The LDL-C levels below 70 mg/dL (1.8 mmol/L) were associated with a 26% reduction in the risk of all-cause dementia and a 28% reduction in the risk of ADRD, compared with levels above 130 mg/dL (3.4 mmol/L). For LDL-C levels below 55 mg/dL (1.4 mmol/L), there was an 18% risk reduction for both outcomes. Among those with LDL-C <70 mg/dL (<1.8 mmol/L), statin use was associated with a 13% reduction in all-cause dementia risk and a 12% decrease in ADRD risk compared with non-users.
Conclusion Low LDL-C levels (<70 mg/dL (<1.8 mmol/L)) are significantly associated with a reduced risk of dementia, including ADRD, with statin therapy providing additional protective effects. These findings support the necessity of targeted lipid management as a preventive strategy against dementia, indicating the importance of personalised treatment approaches.
A group of volunteers aged 45 to 65 years old received one of two doses of suvorexant or a placebo pill, an hour after researchers tapped their cerebrospinal fluid to collect a small sample.
It’s a paper from 2023. Sciencealert always republishes old stuff to get clicks. As they note at the end of these republished articles: “An earlier version of this article was published in April 2023.”
“current research shows that DHA mainly crosses the blood–brain barrier in the form of NE-DHA or LPC-DHA.
LPC-DHA in plasma can be converted from PC-DHA catalyzed by phosphatidylcholine-cholesterol acyltransferase. Choline is, in turn, a synthetic precursor of PC
Several studies have shown that single supplementation with fish oil (DHA dietary supplements) does not significantly enrich DHA in the brain [13,14,15] because DHA is released in the form of free DHA or monoacylglycerol during TAG digestion and exists in plasma as TAG, which is not well absorbed by the brain”
Apoe4 probably doesnt get through the whole cycle as well, so direct lpc supplementation is less risky ?
This nutrient, plasmologens, has a broad benefit but posting here on the brain/alzhemers thread given high value for such use:
I watch everything by Alex Kikel. Search youtube on Alex Kikel. He’s got alot of peptide, mitocontrial, anti-aging helps. If I got seriously sick I’d pay what ever his consulting fee is, hes that good. Not limited by a license and the AMA. See his interview with Jay, Hunter on the latest products they are bringing to market. Search for the most recent Q&A. See biolongevitylabs.com and new products like BioMind. I take the sub components and these products are expensive but still cheaper then buying the ingredients separately.
There’s no alternative besides very high end foods for plasmologens then https://prodrome.com
We buy frozen fish roe and eat an oz every AM. We take many of the freeze dried organ pills, liver etc, 2 raw eggs with my pint of bone broth mix every AM. We buy low PUFA eggs, no corn or soy… Plasmologens in many nutrient dense food. But prodrome at least is a measured dose of these plasmologens. I’m on a subscription to save a few…
Sorry, I don’t remember. I was never very convinced of the benefits of copious supplementation with fishoil, so I wasn’t that motivated to pay attention to brands. I do take 500mg EPA only three times a week, but that’s it.
Cardiorespiratory fitness and cardiometabolic health are associated with distinct cognitive domains in cognitively healthy older adults.
Background: Aging is associated with progressive cognitive decline, as well as increased prevalence of cardiometabolic risk factors and reduced cardiorespiratory fitness. In fact, reduced cardiometabolic health and cardiorespiratory fitness are both associated with a decline in cognitive functioning. This study examines the common and distinct contributions of these cardiovascular health factors on cognitive variability across different domains in cognitively healthy older adults.
I bought some of this LPC supplement so I hope it work. It seems like its most surefire way to get some into the brain, and maybe the only way in some studies. But I did find this study that showed maybe even LPC-DHA does not get into brain, only the EPA. Is anyone able to download the full study? https://www.plefa.com/article/S0952-3278(24)00055-3/abstract
Seems like NAD boosters (NMN, NR, etc.) may not be so helpful in the quest to maintain brain function and cardiovascular health (though I’m unsure of the influence of the APOE knockout status of the mice used in the study and how that translates to human issues).
“obviously 8 completed human clinical trials showing anti-inflammatory effects of NR in ppl are more convincing than an experiment in a mutant mouse strain”
It is all part of this question as to whether you can have two much of a B3 vitamer, whether this relates to all of them or only a limited subset.
Since that discovery of a blood biomarker for Alzheimer’s disease, there has been remarkable further advances, including the availability of the test over the past year at a cost of approximately $200.
In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease pathology with remarkable accuracy (see Part 7 of this series). How about in the general population? Could these tests catch people in the early stages of AD, before they turn up at their doctor with memory concerns?
What did they find? Schöll shared some hot-off-the-press data. “We’ve only had it a few days, so it is very preliminary,” he told the audience in Vienna. Still, some patterns may be emerging. The neotiv neotiv | Enabling cognitive health cognitive test appears to correlate with age, with older people scoring lower. Men performed worse than women across all ages; though the difference was slight, it was consistent, said Schöll.
Intriguingly, plasma p-tau217 rose with age, and more so among people who tested positive for amyloid. This was slightly different than Sebastian Palmqvist, Lund University, reported for primary care settings. There too, the marker inched up with age in people who were amyloid-negative, but the opposite was true among the amyloid-positives (see Part 7 of this series). In REAL AD, baseline numbers were slightly higher in people who carried an ApoE4 allele.
